China Cognition and Aging Study
A legfontosabb adatok
- Ki végzi
- Capital Medical University
- Hol
- Anshan, Baotou, Changchun, Changping, Chaoyang, Dalian, Fengtai, Fujian, Guangzhou, Guiyang, Haerbin, Haidian, Handan, Hangzhou, Hefei, Huangpu, Jinan, Jining, Kaifeng, Luwan, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Putong, Qingdao, Shenyang, Shijiazhuang, Subei, Tai’an, Taiyuan, Tangshan, Ürümqi, Wenzhou, Wuhan, Xi’an, Xianshuigu, Xiaobailou, Xicheng, Xuzhou, Yinchuan, Yuzhong, Zhengzhou, Zhijiazhuang, Zhongshan és Zigong (Kína)Mind a 65 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 100 000 fő, tervezett
- Kezdés
- 2000. jan. 1.
- Várható befejezés
- 2038. jan. 1.
- A vizsgálat típusa
- Megfigyeléses, 6 csoport
- A regiszteradat frissítve
- 2026. március 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan embereket keres, akiknek memória- vagy gondolkodási zavaruk van (enyhe kognitív zavar, Alzheimer-kór, vaszkuláris demencia), valamint normál gondolkodású embereket, és őket hosszabb ideig követi.
- Életkor
- Közösségi csoport: 55 éves vagy idősebb. Kórházi csoport: 18 éves vagy idősebb.
- Nem
- Minden nem csatlakozhat.
- A betegség stádiuma
- Több csoport: enyhe kognitív zavar (CDR = 0.5, még nem demencia), Alzheimer-kór (szórványos vagy családi), vaszkuláris demencia, vagy normál gondolkodás (normál MMSE és MoCA pontszám).
A részvétel fő kizáró okai
- Más agyi betegség, amely agyi működészavart okozhat, például agydaganat, Parkinson-kór vagy epilepszia
- Más betegség, amely gondolkodási zavart okozhat, például máj-, vese- vagy pajzsmirigy-elégtelenség, szifilisz, HIV-fertőzés, alkohol- vagy kábítószer-használat
- Értelmi vagy idegrendszeri fejlődési zavar
- Az MRI vizsgálat ellenjavallata
- Ha valaki nem ad vért, vagy nem írja alá a beleegyező nyilatkozatot
A regiszter feltételei, szó szerint
Mind a 63 feltétel megnézéseKevesebb
Ki vehet részt
- Diagnosis according to 2004 Peterson's MCI criteria
- CDR = 0.5
- Memory loss is prominent, and may also be with other cognitive domain dysfunction
- Insidious onset, slow progress
- Not reaching the level of dementia
- Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria
- Subjects and their informed persons can complete relevant and follow- up examinations
- Subjects or their authorized legal guardians sign the informed consent
- Written informed consent obtained from participant or legal guardian prior to any study-related procedures
- Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD)
- Aged 18 (inclusive) or older
- At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria
- Diagnosis for probable VaD according to NINDS-AIREN diagnostic criteria
- MRI inclusion criteria:
- All patients who meet clinical inclusion criteria should accept MRI scans which include an assessment of hippocampal volume
- multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus
- no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis)
- no hippocampus or entorhinal cortex atrophy (MTA score = 0 point)
- Aged 18 (inclusive) or above
- Normal MMSE and MoCA evaluations. MMSE>19 points for illiteracy, >24 points for those educated less than 7 years, >27 points for those educated equal to or more than 7 years. MoCA>13 points for illiteracy, >19 points for those educated less than 7 years, >24 points for those educated equal to or more than 7 years
Ki nem vehet részt
- With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points)
- Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.)
- Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.)
- Suffering from a disease that cannot be combined with cognitive examination
- Refuse to sign the informed consent at baseline; (2) Sporadic Alzheimer's disease (SAD)
- With a family history of dementia
- Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.)
- Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.)
- Suffering from a disease that cannot be combined with cognitive examination
- Refuse to sign the informed consent at baseline; (3) Familial Alzheimer's disease (FAD)
- Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD)
- Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer
- Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments
- With history of alcohol or drug abuse
- Refuse to sign the informed consent at baseline; (4) Vascular dementia (VaD)
- Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.)
- Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.)
- With a history of mental illness or those with congenital mental retardation
- Suffering from a disease that cannot be combined with a cognitive examination
- Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI
- Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.)
- Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.)
- Suffering from a disease that cannot be combined with a cognitive examination
- MRI and laboratory tests do not support or rule out a diagnosis of AD
- Mental and neurodevelopmental retardation
- Contraindications to MRI
- Refuse to draw blood
- Mental and neurodevelopmental retardation
- Contraindications to MRI
- Refuse to draw blood
- Pregnant or lactating women
- No reliable insiders
- Contraindications to MRI
- Refuse to draw blood
- Refuse to sign informed consent; (5) Normal control
- Subjects with abnormal MMSE or MoCA scores
- Mental and neurodevelopmental retardation
- Contraindications to MRI
- Refuse to draw blood
- Refuse to sign the informed consent at baseline
Egyéb feltételek
- Community population: age ≥ 55 years, male or female, with consent to participant the study
- Hospital population: subjects are all over 18 years old. Through clinical evaluation, neuropsychological test, imaging examination, blood and cerebrospinal fluid examination, etc, we will comprehensively evaluate the cognitive function and various test measures
- (1) MCI and its subtypes
Helyszínek itt: Kína
- Changda Hospital, AnshanAnshan, KínaContact: Xiu Han, DoctorRésztvevőt keres
- Baotou Central HospitalBaotou, KínaContact: Furu Liang, DoctorRésztvevőt keres
- China-Japan friendship Hospital of Jilin universityChangchun, KínaContact: Qin Zhao, DoctorRésztvevőt keres
- The First Hospital of Jilin UniversityChangchun, KínaContact: Li Sun, DoctorRésztvevőt keres
- Beijing Geriatric HospitalChangping, KínaContact: Jihui LvRésztvevőt keres
- Beijing Chao Yang HospitalChaoyang, KínaContact: Yue Wang, DoctorRésztvevőt keres
- China-Japan Friendship HospitalChaoyang, KínaContact: Dantao PengRésztvevőt keres
- Affiliated Zhongshan Hospital of Dalian UniversityDalian, KínaContact: Qiang Ma, DoctorRésztvevőt keres
- The First Affiliated Hospital of Dalian Medical UniversityDalian, KínaContact: Cui Wang, DoctorRésztvevőt keres
- Dongfang Hospital Affiliated to Beijing University of Chinese MedicineFengtai, KínaContact: Lanxiang Jin, DoctorRésztvevőt keres
- Fujian Medical University Union HospitalFujian, KínaContact: Qinyong YeRésztvevőt keres
- Guangzhou Psychiatric HospitalGuangzhou, KínaContact: Mouni Tang, DoctorRésztvevőt keres
- The Affiliated Hospital of Guizhou Medical UniversityGuiyang, KínaContact: Lan Chu, DoctorRésztvevőt keres
- First Affiliated Hospital of Harbin Medical UniversityHaerbin, KínaContact: Shurong Duan, DoctorRésztvevőt keres
- Chinese PLA General HospitalHaidian, KínaContact: Jianjun Jia, DoctorRésztvevőt keres
- Fu Xing Hospital, Capital Medical UniversityHaidian, KínaContact: Fang Li, DoctorRésztvevőt keres
- Peking University Third HospitalHaidian, KínaContact: Weizhong XiaoRésztvevőt keres
- Handan Central HospitalHandan, KínaContact: Minchen Kan, DoctorRésztvevőt keres
- First Affiliated Hospital of Zhejiang UniversityHangzhou, KínaContact: Benyan Luo, DoctorRésztvevőt keres
- Shao Yifu Hospital of Zhejiang Medical UniversityHangzhou, KínaContact: Peilin Lu, DoctorRésztvevőt keres
- Zhejiang Provincial People's HospitalHangzhou, KínaContact: Enyan YuRésztvevőt keres
- The First Affiliated Hospital of Anhui Medical UniversityHefei, KínaContact: Yanghua Tian, DoctorRésztvevőt keres
- Shanghai Changzheng HospitalHuangpu, KínaContact: Jianhua Zhuang, DoctorRésztvevőt keres
- Qilu Hospital of Shandong UniversityJinan, KínaContact: Peiyan Shan, DoctorRésztvevőt keres
- Shandong Provincial HospitalJining, KínaContact: Yifeng Du, DoctorRésztvevőt keres
- Kaifeng Central HospitalKaifeng, KínaContact: Huanrong Yu, DoctorRésztvevőt keres
- Ruijin HospitalLuwan, KínaContact: Gang Wang, DoctorRésztvevőt keres
- Jiangxi Provincial People's HospitalNanchang, KínaContact: Kunnan Zhang, DoctorRésztvevőt keres
- Affiliated Hospital of North Sichuan Medical CollegeNanchong, KínaContact: Ying Ma, DoctorRésztvevőt keres
- First Affiliated Hospital of Guangxi Medical UniversityNanning, KínaContact: Shengliang LiangRésztvevőt keres
- Nantong University Affiliated HospitalNantong, KínaContact: Maohong Cao, DoctorRésztvevőt keres
- Ningbo City Medical Treatment Center Lihuili HospitalNingbo, KínaContact: Guomin Xie, DoctorRésztvevőt keres
- RenJi HospitalPutong, KínaContact: Qun Xu, DoctorRésztvevőt keres
- Qilu Hospital of Shandong University (Qingdao)Qingdao, KínaContact: Bin Liang, DoctorRésztvevőt keres
- QingDao Municipal HospitalQingdao, KínaContact: Lan Tan, DoctorRésztvevőt keres
- The Affiliated Hospital of Qingdao UniversityQingdao, KínaContact: Jinping Sun, DoctorRésztvevőt keres
- First Hospital of China Medical UniversityShenyang, KínaContact: Yunpeng Cao, DoctorRésztvevőt keres
- First Hospital of Shijiazhuang CityShijiazhuang, KínaContact: Huiying ZhaoRésztvevőt keres
- Subei People's Hospital of JiangsuSubei, KínaContact: Jun Xu, DoctorRésztvevőt keres
- The 88th Hospital of PLATai’an, KínaContact: Jintao Zhang, DoctorRésztvevőt keres
- The First Affiliated Hospital of Shanxi Medical UniversityTaiyuan, KínaContact: Yuling Tian, DoctorRésztvevőt keres
- Tangshan Worker's HospitalTangshan, KínaContact: Yongqiu Li, DoctorRésztvevőt keres
- Traditional Chinese Medicine Hospital of Xinjiang Autonomous RegionÜrümqi, KínaContact: Xinling MengRésztvevőt keres
- First Affiliated Hospital of Wenzhou Medical UniveristyWenzhou, KínaContact: Zhen WangRésztvevőt keres
- People's Hospital Affiliated Hubei Medical UniversityWuhan, KínaContact: Jianjun Zhang, DoctorRésztvevőt keres
- The Third Xiangya Hospital of Central South UniversityWuhan, KínaContact: Lu ShenRésztvevőt keres
- Tongji HospitalWuhan, KínaContact: Min ZhangRésztvevőt keres
- Wuhan University Zhongnan HospitalWuhan, KínaContact: Hanxing LiuRésztvevőt keres
- Xiangya Hospital of Central South UniversityWuhan, KínaContact: Qiuyun Tu, DoctorRésztvevőt keres
- First Affiliated Hospital Xi'an Jiaotong UniversityXi’an, KínaContact: Qiumin Qu, DoctorRésztvevőt keres
- Tang-Du HospitalXi’an, KínaContact: Wei Zhang, DoctorRésztvevőt keres
- Tianjin Huanhu HospitalXianshuigu, KínaContact: Yuying Zhou, DoctorRésztvevőt keres
- Tianjin Medical University General HospitalXiaobailou, KínaContact: Nan Zhang, DoctorRésztvevőt keres
- Peking Union Medical College HospitalXicheng, KínaContact: Jing Gao, DoctorRésztvevőt keres
- Peking University First HospitalXicheng, KínaContact: Zhirong JiaRésztvevőt keres
- Mineral General Hospital, XuzhouXuzhou, KínaContact: Liangqun Rong, DoctorRésztvevőt keres
- General Hospital of Ningxia Medical UniversityYinchuan, KínaContact: Qin Zhang, DoctorRésztvevőt keres
- The People's Hospital of NingxiaYinchuan, KínaContact: Yongying Gao, DoctorRésztvevőt keres
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityYuzhong, KínaContact: Yanjiang WangRésztvevőt keres
- The Second Affiliated Hospital of Chongqing Medical UniversityYuzhong, KínaContact: Yangmei ChenRésztvevőt keres
- Henan Provincial People's HospitalZhengzhou, KínaContact: Jiewen Zhang, DoctorRésztvevőt keres
- People's Hospital of ZhengzhouZhengzhou, KínaContact: Shuling Zhang, DoctorRésztvevőt keres
- Hebei General HospitalZhijiazhuang, KínaContact: Peiyuan Lv, DoctorRésztvevőt keres
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityZhongshan, KínaContact: Jun Liu, DoctorRésztvevőt keres
- Zigong First People's HospitalZigong, KínaContact: Xiaoya Xu, DoctorRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate prevention and treatment strategies for dementia. The primary aims of China COAST are as follows:
A teljes eredeti leírásKevesebb
1. To use the prospective cohort to establish a large database research platform, so as to provide comprehensive epidemiological data, clinical and neuropsychological evaluation data, biological samples, and laboratory tests and imaging data. 2. To update the prevalence and incidence rate of dementia and its subtypes every 2-3 years, and clarify the conversion pattern from normal elderly to MCI and from MCI to dementia. 3. To explore the known or unknown protective and risk factors of dementia and its major subtypes (AD, VaD, other dementia). 4. To discover new pathogenic genes and susceptible genes of dementia and its major subtypes (AD and VaD), as well as new mutation sites of known pathogenic genes. To study the genetic variation, mutation and polymorphism of PSEN1, PSEN2, APP and APOE genes in dementia patients, and to understand their distribution and roles in the pathogenesis. 5. To study the biomarkers (body fluid, genetics, imaging) with diagnostic value of MCI, AD (sporadic and familial) and VaD, to define their cut-off values, and to establish prediction models. 6. To study the diagnostic criteria of cognitive normal, MCI, dementia and their subtypes (clinical and molecular subtypes) in the cohort, and to make psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people. 7. To find potentially modifiable risk factors for dementia and to study the prevention and intervention effect of non-pharmacological treatment on APOE ε4 carriers, MCI and AD or other dementia patients,which included improvements in education, nutrition, health care, and lifestyle changes. This needs a long time follow-up. 8. To explore the relationship between dementia as well as its major subtype AD and cerebral and systemetic circulatory disorders (for example, mixed dmentia), as well as potential therapeutic strategies. 9. To carry out investigation and researches about dementia related education, improve the awareness of dementia, and strengthen the management of dementia. 10. To investigate the level of stigma and discrimination and its influencing factors in patients with Alzheimer's disease and their caregivers.
A vizsgálat 6 csoportja
- Mild cognitive impairment (MCI) and its subtypes
MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
- Sporadic Alzheimer's disease (SAD)
SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
- Familial Alzheimer's disease (FAD)
FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
- Vascular dementia(VaD)
VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
- Normal control
Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
- Non-Alzheimer degenerative dementia
Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- Publikációk
- Joint impact of pathological burden and cognitive resilience on Alzheimer's disease risk.Nature medicine, 2026
- The Effect of APOE ε4 on Alzheimer's Disease Fluid Biomarkers: A Cross-Sectional Study Based on the COAST.CNS neuroscience & therapeutics, 2025
- Biomarker Changes during 20 Years Preceding Alzheimer's Disease.The New England journal of medicine, 2024
- A regiszteradat frissítve
- 2026. március 23.